Xencor (XNCR) Total Current Liabilities (2013 - 2026)
Xencor (XNCR) posted quarterly Total Current Liabilities of $73.5 million for Q1 2026, down 16.94% year-over-year from $88.4 million in Q1 2025, and down 23.41% quarter-over-quarter from $95.9 million in Q4 2025.
Analysis
Xencor (XNCR) Total Current Liabilities (2013 - 2026) Analysis & Trends
Xencor (XNCR) has reported Total Current Liabilities for 14 consecutive years, with $73.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities fell 16.94% year-over-year to $73.5 million; the TTM figure through Mar 2026 stood at $73.5 million (down 16.94% YoY), while the FY2025 annual figure was $95.9 million, up 9.69% from the prior year.
- Total Current Liabilities declined to $73.5 million in Q1 2026 per XNCR's latest filing, from $95.9 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $96.1 million in Q2 2025 and bottomed at $44.6 million in Q2 2023.
- Historically, Total Current Liabilities has averaged $76.0 million across 5 years, with a median of $75.0 million in 2022.
- Annual changes were most pronounced in 2022 — Total Current Liabilities soared 103.15% — and 2023, when it slumped 41.09%.
- Xencor's Total Current Liabilities stood at $63.8 million in 2022, then advanced by 15.77% to $73.9 million in 2023, then advanced by 18.29% to $87.4 million in 2024, then advanced by 9.69% to $95.9 million in 2025, then dropped by 23.41% to $73.5 million in 2026.
- Business Quant data shows XNCR's Total Current Liabilities at $73.5 million in Q1 2026, $95.9 million in Q4 2025, and $86.5 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 2.53 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 354.06 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 2.12 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.51 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 630.93 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Xencor | 2.02 Bn | 1.65 Bn | - | 81.87 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 81.87 Mn |
| Mar 31, 2026 | 73.46 Mn |
| Dec 31, 2025 | 95.91 Mn |
| Sep 30, 2025 | 86.49 Mn |
| Jun 30, 2025 | 96.08 Mn |
| Mar 31, 2025 | 88.44 Mn |
| Dec 31, 2024 | 87.43 Mn |
| Sep 30, 2024 | 90.81 Mn |
| Jun 30, 2024 | 75.59 Mn |
| Mar 31, 2024 | 71.08 Mn |
| Dec 31, 2023 | 73.92 Mn |
| Sep 30, 2023 | 53.04 Mn |
| Jun 30, 2023 | 44.63 Mn |
| Mar 31, 2023 | 65.06 Mn |
| Dec 31, 2022 | 63.84 Mn |
| Sep 30, 2022 | 90.03 Mn |
| Jun 30, 2022 | 75.04 Mn |
| Mar 31, 2022 | 60.94 Mn |
| Dec 31, 2021 | 70.74 Mn |
| Sep 30, 2021 | 44.32 Mn |